Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Healthy Subjects
Interventions
DRUG

LV232/Placebo

"Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 60mg Group:~6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally."

DRUG

LV232

"Drug: LV232 20mg Group:~12 subjects will receive LV232 20mg, orally~Drug: LV232 60mg Group:~12 subjects will receive LV232 60mg, orally"

Trial Locations (1)

Unknown

RECRUITING

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY